AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q4 EPS of $2.16, $0.10 better than the analyst estimate of $2.06. Revenue for the quarter came in at $15.1 billion versus the consensus estimate of $14.82 billion.

GUIDANCE:

AbbVie sees FY2025 EPS of $12.12-$12.32, versus the consensus of $12.13.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Abu Dhabi's G42 Weighs US Ownership To Safeguard AI Chip Access - Bloomberg
• StoneX Reiterates Hold Rating on Old Dominion Freight Line (ODFL) on QTD Operating Metrics
• Change in Nonfarm Payrolls (Aug) 162K vs 55K Expected, Unemployment Rate 4.1%